Newly Popular Drug Boosts Survival in Metastatic TNBC
Triple-destructive breast most cancers (TNBC) sufferers noticed a vital survival income when treated with third-line sacituzumab govitecan (Trodelvy) pretty than chemotherapy, piece III findings from the ASCENT trial confirmed. The trial met it be predominant endpoint, making improvements to median…